Key facts
- Researchers in Hong Kong are developing an affordable blood test for cancer detection.
- The new blood test could eliminate the need for invasive biopsies.
- Guardant Health has launched its Shield MCD test in Asia.
- The Shield MCD test is available in Hong Kong.
- Guardant Health partnered with Manulife for the Shield MCD test launch.
- The Shield MCD test screens for 10 common cancers.
A new, affordable blood test is under development in Hong Kong with the potential to revolutionize cancer detection by eliminating the need for painful and invasive biopsies. This innovative approach aims to provide a less intrusive method for screening multiple types of cancer. The development is part of a broader trend towards more accessible and less invasive diagnostic tools.
In parallel, Guardant Health has launched its Shield MCD test in Asia, with Hong Kong being one of the markets where it is now available. This launch is facilitated through a partnership with Manulife. The Shield MCD test is designed for the early detection of 10 common types of cancer, offering another option for individuals seeking proactive health monitoring. The availability of such tests in the region signifies a growing focus on advanced cancer screening technologies.